4CPS-173 Therapeutic drug monitoring of dalbavancin: a step forward in personalised long-term therapy

View at publisher Summarise with VIRAT
Authors: J Torra Garcia, Rosario Bueno Uceda, Joan Gómez‐Junyent, R Barquin, Mercè Comas Serrano, Daniel Pérez‐Prieto, Albert Alier, ML Sorli Redo, Sònia Luque, AM Juanes
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Background and Importance Dalbavancin is a long-acting lipoglycopeptide active against Gram-positive bacteria exhibiting rapid bactericidal activity. For difficult-to-treat infections, different dosing regimens have been proposed but limited comparative clinical pharmacokinetic (PK) data are available. Although with limited evidence, therapeutic drug monitoring (TDM) has been employed to extend dosing intervals while ensuring optimal drug exposure. Aim and Objectives To evaluate, in a pilot TDM study, whether dalbavancin maintains sufficient plasma concentrations (Cp) at different time points after administration, potentially allowing extended dosing intervals. Material and Methods Prospective PK study conducted in a tertiary hospital including all patients with dalbavancin TDM (November 2024–August 2025). Demographic, clinical, PK and microbiological data were collected. Blood samples were obtained at various time points post-administration: ≤1 week, 1–2 weeks, 2–3 weeks, and >3 weeks. A validated UPLD-MS/MS method was used. Preclinical data suggest that a PK/PD target Cp above 4–8 mg/L before the next dose is sufficient to ensure efficacy against staphylococci (MIC ≤0.125 mg/L). Results Twenty-two patients were included (50% women). Characteristics (median (range)): age 72 (28–95) years, Body Mass Index: 26.6(17.8–38.8) kg/m2, Charlson Index: 2 (0–6), baseline glomerular filtration rate: 80(31–119) mL/min, serum creatinine: 0.9(0.5–1.7) mg/dL. Infection sites: osteoarticular (72.7%) and endovascular (27.3%). Targeted therapy was used in 20 patients (90.9%), being polymicrobial infections in seven (31.8%). Main microorganisms were: coagulase-negative staphylococci in 12 (41.4%) patients, MRSA in seven (24.1%), E. faecalis in four (13.8%), and MSSA in three (10.3%). MIC data were available for eight isolates (36.4%), of which 87.5% showed MIC

Fields of Study & Subjects

Antibiotics Pharmacokinetics and Efficacy Antimicrobial Resistance in Staphylococcus Pharmaceutical studies and practices

Publication details

Journal / source
European Journal of Hospital Pharmacy
Pages
A135.1–A135
Publication date
1 March 2026
Language
EN